CClinicalTrials.gg
CompletedNCT00829478AFIBUpdated Mar 20, 2012

Improving the Quality of Care for Atrial Fibrillation by Promoting Patient-Centered Decision Making

A Phase 1 interventional study of Decision Aid for Atrial Fibrillation and Usual Care in Atrial Fibrillation, sponsored by VA Connecticut Healthcare System. Completed at 1 site in United States. Open to participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-03-20.

Sponsored by VA Connecticut Healthcare System · Phase 1 and Interventional

Phase
Phase 1
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Study summary

The primary aim of this proposal is to determine the effectiveness of a decision support tool on improving the process of shared decision-making for treatment on nonvalvular atrial fibrillation (NVAF) compared to receipt of usual care.

Read the detailed description

Decision-making regarding appropriate therapy for non-valvular atrial fibrillation (NVAF) is a complex process. Different options carry with them different profiles of risks and benefits, and choosing the "right" therapy depends upon the patient's understanding of these risks and benefits and a consideration of the risks and benefits according to the patient's values and preferences. Studies have shown that patients' preferred therapy frequently disagrees with what is recommended by disease management guidelines.

The purpose of this study is to examine an intervention to improve the quality of decision-making for NVAF compared to usual care. The intervention has several components, including: a) educating the patient about why values and preferences are important to the decision-making process, b) providing an individualized assessment of the risks and benefits of each of the treatment options, c) exploring patients' values and preferences as they relate to the risks and benefits of each of the treatment options, d) preparing the patient to discuss his/her preferences with the physician.

02

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • Atrial fibrillation
  • Cerebrovascular accident
  • Anticoagulation
  • Decision-making
03

In context

Atrial Fibrillation

3,869 studies on the registry are indexed under Atrial Fibrillation; 923 are open to participants now.

This study's enrollment of 135 is close to the median of 144 across 2,380 interventional studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

VA Connecticut Healthcare System is the lead sponsor of 40 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 45 years or older
  • Be scheduled to see primary Doctor at VA
  • Diagnosis of atrial fibrillation
  • English speaking

Exclusion criteria

Exclusion Criteria:

  • Have valvular disease as the cause of Afib
  • Be on warfarin for a condition other than NVAF
  • Have a contraindication to warfin
  • Have a contraindication to ASA
  • Life expectancy of less than 12 months
  • Cognitive impairment
  • Receiving anti-platelet agent other than aspirin
  • Receiving care in a supervised resident clinic or from an attending physician who refuses participation in the study
  • Bleed with identified source in the last 12 months
  • Bleed with an unidentified source
  • History of intracerebral hemorrhage
  • Severe hearing impairment
  • Severe visual impairment
05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
135 participants (actual)

Study arms

  • Placebo comparator
    1

    Usual Care

    Other: Usual Care

  • Experimental
    2

    Intervention

    Behavioral: Decision Aid for Atrial Fibrillation

Interventions

  • BehavioralDecision Aid for Atrial Fibrillation

    Single contact educational session

  • OtherUsual Care

    Usual Care

06

What researchers measure

Primary outcomes

  1. Decisional conflict

    Time frame: Immediately following and 1-month post-intervention

Secondary outcomes

  1. Knowledge regarding atrial fibrillation

    Time frame: Immediately following study intervention and 1 month post-intervention

  2. Anxiety

    Time frame: Immediately following intervention and 1 month post-intervention

  3. Changes in treatment plan for atrial fibrillation

    Time frame: Within 30 days post-intervention

  4. Quality of clinician-patient communication

    Time frame: Clinician visit immediately post-intervention

07

Study locations

1 site
  • VA Connecticut Healthcare System - West Haven Campus
    West Haven, Connecticut 06516, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 20, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00829478
Lead sponsor
VA Connecticut Healthcare System
Collaborators
Donaghue Medical Research Foundation, Yale University
Responsible party
Sponsor
First posted
Jan 27, 2009
Start date
Oct 2008
Primary completion
May 2010
Completion
Jun 2010
Last update
Mar 20, 2012

Study contacts

Terri R Fried, M.D.
principal investigator · VA Connecticut HS

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion